CN103748110A - 具有增加的FcRn结合的抗原结合蛋白 - Google Patents

具有增加的FcRn结合的抗原结合蛋白 Download PDF

Info

Publication number
CN103748110A
CN103748110A CN201280034887.5A CN201280034887A CN103748110A CN 103748110 A CN103748110 A CN 103748110A CN 201280034887 A CN201280034887 A CN 201280034887A CN 103748110 A CN103748110 A CN 103748110A
Authority
CN
China
Prior art keywords
seq
binding protein
antigen binding
antigen
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280034887.5A
Other languages
English (en)
Chinese (zh)
Inventor
J.H.埃利斯
M.J.莫洛伊
T.沙
I.M.汤姆林森
A.亚辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44586854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103748110(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN103748110A publication Critical patent/CN103748110A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201280034887.5A 2011-07-19 2012-07-19 具有增加的FcRn结合的抗原结合蛋白 Pending CN103748110A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1112429.4A GB201112429D0 (en) 2011-07-19 2011-07-19 Antigen-binding proteins with increased FcRn binding
GB1112429.4 2011-07-19
PCT/EP2012/064129 WO2013011076A2 (en) 2011-07-19 2012-07-19 Antigen-binding proteins with increased fcrn binding

Publications (1)

Publication Number Publication Date
CN103748110A true CN103748110A (zh) 2014-04-23

Family

ID=44586854

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280034887.5A Pending CN103748110A (zh) 2011-07-19 2012-07-19 具有增加的FcRn结合的抗原结合蛋白

Country Status (22)

Country Link
US (1) US20130243764A1 (cg-RX-API-DMAC10.html)
EP (2) EP2734548B1 (cg-RX-API-DMAC10.html)
JP (1) JP2014524748A (cg-RX-API-DMAC10.html)
KR (1) KR20140054085A (cg-RX-API-DMAC10.html)
CN (1) CN103748110A (cg-RX-API-DMAC10.html)
AU (1) AU2012285786B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014000341A2 (cg-RX-API-DMAC10.html)
CA (1) CA2841105A1 (cg-RX-API-DMAC10.html)
CL (1) CL2014000134A1 (cg-RX-API-DMAC10.html)
CO (1) CO6862106A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140029A (cg-RX-API-DMAC10.html)
DO (1) DOP2014000007A (cg-RX-API-DMAC10.html)
EA (1) EA201391789A1 (cg-RX-API-DMAC10.html)
ES (1) ES2600854T3 (cg-RX-API-DMAC10.html)
GB (1) GB201112429D0 (cg-RX-API-DMAC10.html)
MA (1) MA35345B1 (cg-RX-API-DMAC10.html)
MX (1) MX2014000739A (cg-RX-API-DMAC10.html)
PE (1) PE20141660A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014500167A1 (cg-RX-API-DMAC10.html)
SG (1) SG10201601154QA (cg-RX-API-DMAC10.html)
WO (1) WO2013011076A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201400062B (cg-RX-API-DMAC10.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456538A (zh) * 2014-05-23 2017-02-22 阿雷斯贸易股份有限公司 液体药物组合物
WO2018129713A1 (zh) * 2017-01-13 2018-07-19 杭州翰思生物医药有限公司 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法
CN110167531A (zh) * 2017-01-11 2019-08-23 赛特瑞恩股份有限公司 稳定的液体调配物
CN111032688A (zh) * 2017-08-11 2020-04-17 研究发展基金会 用于延长的血清半衰期的工程化抗体fc变体
CN115770292A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的协同免疫及其用途
CN115770291A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用
CN115772227A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用
WO2023098694A1 (zh) * 2021-11-30 2023-06-08 江苏恒瑞医药股份有限公司 一种抗sost抗体药物组合物及其用途

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186361A1 (en) 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20160105535A (ko) 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158275A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2863951A1 (en) * 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
FR2999431B1 (fr) * 2012-12-17 2016-03-18 Lfb Biotechnologies Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
EP2931749B1 (fr) * 2012-12-17 2019-04-24 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
WO2014114651A1 (en) * 2013-01-24 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Tnf-alpha antigen-binding proteins
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
BR112015017307A2 (pt) * 2013-03-14 2017-11-21 Abbvie Inc composições de espécies com baixa acidez e métodos para produção e uso das mesmas
ES2688726T5 (es) * 2013-07-19 2022-06-27 Hexal Ag Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) * 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
CA2959629C (en) 2014-09-03 2023-10-31 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
EP3250598A1 (en) * 2015-01-28 2017-12-06 Mabxience S.A. Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
CN109071631B (zh) 2016-03-14 2023-07-14 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
CA3027018A1 (en) 2016-07-29 2018-02-01 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
US11286295B2 (en) * 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
KR20260090008A (ko) 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
BR112020015006A2 (pt) * 2018-01-26 2020-12-29 Genzyme Corporation Variantes de fc com ligação realçada ao fcrn e meia-vida prolongada
MX2021010611A (es) * 2019-03-05 2021-11-12 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Aves con genoma editado.
CN114466663B (zh) 2019-07-25 2026-01-02 建新公司 以FcRn拮抗剂治疗抗体介导的障碍的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163699A1 (en) * 2004-11-12 2009-06-25 Chamberlain Aaron Keith Fc VARIANTS WITH ALTERED BINDING TO FcRn

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7658921B2 (en) * 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1355919B1 (en) * 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
EP2684895A1 (en) * 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
CN101848936B (zh) 2007-08-20 2017-05-03 葛兰素集团有限公司 生产方法
TW200944231A (en) * 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
WO2009073805A2 (en) * 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
EP2225276B1 (en) * 2007-12-31 2014-04-23 Bayer Intellectual Property GmbH Antibodies to tnf alpha
FR2934599B1 (fr) 2008-07-29 2012-12-21 Arkema France Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations
RU2481824C2 (ru) * 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EA201190273A1 (ru) * 2009-05-28 2012-12-28 Глаксо Груп Лимитед Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз
WO2011074965A1 (en) * 2009-12-17 2011-06-23 Stichting Sanquin Bloedvoorziening Methods and means for counteracting an activity of an fc domain
TWI603739B (zh) 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗-TNFα抗體之液體調配物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163699A1 (en) * 2004-11-12 2009-06-25 Chamberlain Aaron Keith Fc VARIANTS WITH ALTERED BINDING TO FcRn

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A DATTA-MANNAN ET AL: "Monoclonal antibody clearance:impact of modulating the interaction of IgG with the neonatal Fc receptor", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 282, no. 3, 1 January 2007 (2007-01-01), pages 1709 - 1717, XP055043665, DOI: doi:10.1074/jbc.M607161200 *
DALL ACQUA W F ET AL: "Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor(FcRn)", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 281, no. 33, 21 June 2006 (2006-06-21), XP002404904, DOI: doi:10.1074/jbc.M604292200 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456538A (zh) * 2014-05-23 2017-02-22 阿雷斯贸易股份有限公司 液体药物组合物
CN110167531A (zh) * 2017-01-11 2019-08-23 赛特瑞恩股份有限公司 稳定的液体调配物
CN110167531B (zh) * 2017-01-11 2025-06-03 赛特瑞恩股份有限公司 稳定的液体调配物
WO2018129713A1 (zh) * 2017-01-13 2018-07-19 杭州翰思生物医药有限公司 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法
CN111032688A (zh) * 2017-08-11 2020-04-17 研究发展基金会 用于延长的血清半衰期的工程化抗体fc变体
CN115770292A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的协同免疫及其用途
CN115770291A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用
CN115772227A (zh) * 2021-09-08 2023-03-10 珠海市丽珠单抗生物技术有限公司 新型冠状病毒SARS-CoV-2的Delta变异株疫苗与应用
WO2023098694A1 (zh) * 2021-11-30 2023-06-08 江苏恒瑞医药股份有限公司 一种抗sost抗体药物组合物及其用途

Also Published As

Publication number Publication date
BR112014000341A2 (pt) 2017-02-14
NZ618897A (en) 2016-02-26
GB201112429D0 (en) 2011-08-31
JP2014524748A (ja) 2014-09-25
US20130243764A1 (en) 2013-09-19
EP3009450A1 (en) 2016-04-20
CA2841105A1 (en) 2013-01-24
MA35345B1 (fr) 2014-08-01
WO2013011076A3 (en) 2013-04-04
CL2014000134A1 (es) 2014-07-25
PE20141660A1 (es) 2014-11-21
WO2013011076A2 (en) 2013-01-24
AU2012285786A1 (en) 2014-02-06
KR20140054085A (ko) 2014-05-08
EP2734548B1 (en) 2016-08-17
CO6862106A2 (es) 2014-02-10
ZA201400062B (en) 2017-08-30
AU2012285786B2 (en) 2016-05-12
MX2014000739A (es) 2014-02-19
EP2734548A2 (en) 2014-05-28
PH12014500167A1 (en) 2019-03-22
CR20140029A (es) 2014-03-05
SG10201601154QA (en) 2016-03-30
DOP2014000007A (es) 2014-04-30
ES2600854T3 (es) 2017-02-13
EA201391789A1 (ru) 2014-06-30

Similar Documents

Publication Publication Date Title
EP2734548B1 (en) Tnf-alpha-antigen-binding proteins against with increased fcrn binding for use in therapy
AU2014209994B2 (en) TNF-alpha antigen-binding proteins
US20240239884A1 (en) SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
KR102307257B1 (ko) 항-il-4/항-il-13 이중특이성 항체 제형
JP7785677B2 (ja) 抗btla抗体医薬組成物及びその使用
KR20120103664A (ko) 전신 홍반성 낭창을 치료하기 위한 인간화된 항-il-10 항체
TWI844034B (zh) 抗IL17a抗體的水性藥物組合物及其用途
CN110612309A (zh) 用于降低免疫原性的方法和组合物
WO2013190047A1 (en) Pharmaceutical formulation
JP2025519612A (ja) Igf1r抗体
WO2022184148A1 (zh) Il-21-抗白蛋白单域抗体融合蛋白药物组合物及其用途
NZ618897B2 (en) Tnf-alpha antigen-binding proteins with increased fcrn binding
KR20250020474A (ko) IgG4-관련 질환을 치료하기 위한 방법 및 조성물
WO2023131213A1 (zh) 一种包含抗FXI/FXIa抗体的药物组合物及其用途
CN119367531A (zh) 抗cd3×cd20双特异性抗体的药物组合物
HK1215194B (en) Solution formulations of engineered anti-il-23p19 antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140423